IL6 and metabolic dysfunction-associated steatotic liver disease: Individuals with MASLD or MASH exhibit elevated plasma levels of interleukin-6 (IL-6) and Tumor Necrosis Factor-alpha (TNF-α), which may interfere with PON1 serum levels [19].